Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,064
  • Shares Outstanding, K 6,916
  • Annual Sales, $ 50,820 K
  • Annual Income, $ -5,340 K
  • 60-Month Beta 1.82
  • Price/Sales 1.19
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALIM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 1.25
  • Number of Estimates 1
  • High Estimate 1.25
  • Low Estimate 1.25
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +345.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.50 +1.06%
on 08/05/21
9.68 -11.26%
on 07/21/21
-0.43 (-4.77%)
since 07/02/21
3-Month
8.40 +2.26%
on 05/14/21
10.50 -18.19%
on 06/11/21
-1.12 (-11.53%)
since 05/05/21
52-Week
3.82 +124.81%
on 11/03/20
12.25 -29.88%
on 03/19/21
+1.61 (+23.07%)
since 08/05/20

Most Recent Stories

More News
Ocular Inflammation Treatment Market Industry Size, Competition, Trends and Growth Opportunities by Region 2021-2028

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 8.59 (-0.46%)
AGN : 193.02 (+0.02%)
NVS : 92.25 (+0.72%)
PFE : 45.06 (-0.29%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market Share Growth, Size Value, Trends, Rigonal outlook by 2028

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report Allergan Plc, Valeant...

AKRX : 0.0900 (-51.01%)
ALIM : 8.59 (-0.46%)
AGN : 193.02 (+0.02%)
NVS : 92.25 (+0.72%)
PFE : 45.06 (-0.29%)
VRX.TO : 30.80 (-3.33%)
Ocular Drug Delivery Mode Market Size, Future Scope, Demands and Projected Industry Growths to 2025

Selbyville, Delaware. The report on Ocular Drug Delivery Mode market is a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections...

ALIM : 8.59 (-0.46%)
CLSD : 5.26 (+3.14%)
OCUL : 10.84 (+3.14%)
VRX.TO : 30.80 (-3.33%)
Global Ocular Inflammation Treatment Market Growth, Latest Trend and Forecast Report 2021-2027 by Eon Market Research

The new release by Eon Market Research with the title , Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2021 to 2027 is intended to give insights into the current trends and...

AKRX : 0.0900 (-51.01%)
ALIM : 8.59 (-0.46%)
AGN : 193.02 (+0.02%)
NVS : 92.25 (+0.72%)
PFE : 45.06 (-0.29%)
VRX.TO : 30.80 (-3.33%)
Diabetic Retinopathy Market ,Competitive Landscape, Growth Factors, Revenue Analysis, 2020-2026

Factors contributing to high CAGR are growing prevalence of diabetes along with rising incidence of blindness. Moreover, increase in purchasing power and the dread of losing vision have augmented the expenditure...

ABT : 122.21 (+0.53%)
ALIM : 8.59 (-0.46%)
AMPE : 1.4500 (+19.83%)
NVS : 92.25 (+0.72%)
PRXL : 88.08 (-0.02%)
PFE : 45.06 (-0.29%)
REGN : 602.47 (+3.70%)
VRX.TO : 30.80 (-3.33%)
Ocular Drug Delivery Technology Market Size, Share, Trends, Analysis and Forecast 2027

The Global is estimated to value over USD 19 billion by 2027 end at a CAGR of over 6.8% during the forecast period 2020 to 2027.

ALIM : 8.59 (-0.46%)
AGN : 193.02 (+0.02%)
SNPHF : 13.5000 (unch)
VRX.TO : 30.80 (-3.33%)
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor...

RDHL : 7.10 (+1.57%)
PHO : 57.20 (-0.35%)
ECOR : 0.9967 (+2.83%)
MKTY : 7.47 (-1.45%)
SLNG : 7.97 (-0.38%)
CECE : 6.76 (+0.15%)
MKGI : 2.27 (+7.08%)
AUUD : 3.04 (-0.33%)
ARHH : 1.7260 (+7.87%)
DLPN : 10.48 (+2.24%)
IMAC : 1.5400 (+0.65%)
COMS : 2.07 (+0.49%)
MYO : 7.92 (+1.41%)
MRVFF : 1.0100 (+4.16%)
MINM : 2.36 (+1.29%)
DTST : 4.33 (+1.88%)
NLSP : 2.56 (unch)
AWH : 4.47 (+1.59%)
ISDR : 27.55 (-0.22%)
BMRA : 3.95 (+8.52%)
ALIM : 8.59 (-0.46%)
LFMD : 10.02 (+3.09%)
ANDA : 9.20 (+3.37%)
BIOL : 0.5643 (+1.15%)
FBIO : 3.23 (+3.19%)
DHX : 3.80 (+1.60%)
MLSS : 1.8300 (-0.54%)
ORGS : 5.28 (+3.53%)
ELYS : 4.19 (+2.95%)
THBRF : 3.2675 (-2.46%)
NMRD : 7.24 (+0.98%)
DXR : 8.92 (-2.15%)
Alimera Sciences, Inc. to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management...

ALIM : 8.59 (-0.46%)
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the...

ALIM : 8.59 (-0.46%)
Alimera Sciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 29, 2021 / Alimera Sciences, Inc. (NASDAQ:ALIM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 9:00...

ALIM : 8.59 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

3rd Resistance Point 8.99
2nd Resistance Point 8.88
1st Resistance Point 8.73
Last Price 8.59
1st Support Level 8.47
2nd Support Level 8.36
3rd Support Level 8.21

See More

52-Week High 12.25
Fibonacci 61.8% 9.03
Last Price 8.59
Fibonacci 50% 8.04
Fibonacci 38.2% 7.04
52-Week Low 3.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar